Contribution of multidrug resistance protein MRP5 in control of cyclic guanosine 5′-monophosphate intracellular signaling in anterior pituitary cells

被引:36
作者
Andric, Silvana A.
Kostic, Tatjana S.
Stojilkovic, Stanko S.
机构
[1] NICHHD, Sect Cellular Signalling, Endocrinol & Reprod Res Branch, Bethesda, MD 20892 USA
[2] Univ Novi Sad, Dept Biol & Ecol, Novi Sad 21000, Serbia
关键词
D O I
10.1210/en.2006-0091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The energy-dependent cyclic nucleotide cellular efflux is operative in numerous eukaryotic cells and could be mediated by multidrug resistance proteins MRP4, MRP5, and MRP8. In pituitary cells, however, the operation of export pumps and their contribution to the control of intracellular cyclic nucleotide levels were not studied previously. Here we show that cellular efflux of cyclic nucleotides was detectable in normal and immortalized GH(3) pituitary cells under resting conditions and was enlarged after concurrent stimulation of cAMP and cGMP production with GHRH, corticotropin-releasing factor, vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and forskolin. In resting and stimulated cells, the efflux pumps transported the majority of de novo-produced cGMP, limiting its intracellular accumulation in a concentration range of 1-2 mu M. In contrast, only a small fraction of cAMP was released and there was a time- and concentration-dependent accumulation of this messenger in the cytosol, ranging from 1-100 mu M. Stimulation and inhibition of cGMP production alone did not affect cAMP efflux, suggesting the operation of two different transport pathways in pituitary cells. The rates of cAMP and cGMP effluxes were comparable, and both pathways were blocked by probenecid and progesterone. Pituitary cells expressed mRNA transcripts for MRP4, MRP5, and MRP8, whereas GH(3) cells expressed only transcripts for MRP5. Down-regulation of MRP5 expression in GH3 cells decreased cGMP release without affecting cAMP efflux. These results indicate that cyclic nucleotide cellular efflux plays a critical role in elimination of intracellular cGMP but not cAMP in pituitary cells and that such selectivity is achieved by expression of MRP5.
引用
收藏
页码:3435 / 3445
页数:11
相关论文
共 59 条
[1]   Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5 [J].
Adachi, M ;
Reid, G ;
Schuetz, JD .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) :1333-1342
[2]   Regulation of adenosine 3′,5′-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells:: Role of cAMP-phosphodiesterase and cAMP efflux [J].
Ahlström, M ;
Lamberg-Allardt, C .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (08) :1335-1340
[3]   Nitric oxide inhibits prolactin secretion in pituitary cells downstream of voltage-gated calcium influx [J].
Andric, SA ;
Gonzalez-Iglesias, AE ;
Van Goor, F ;
Tomic, M ;
Stojilkovic, SS .
ENDOCRINOLOGY, 2003, 144 (07) :2912-2921
[4]   Dependence of soluble guanylyl cyclase activity on calcium signaling in pituitary cells [J].
Andric, SA ;
Kostic, TS ;
Tomic, M ;
Koshimizu, T ;
Stojilkovic, SS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) :844-849
[5]   Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation [J].
Ang, KL ;
Antoni, FA .
JOURNAL OF NEUROCHEMISTRY, 2002, 81 (03) :422-433
[6]   Molecular diversity of cyclic AMP signalling [J].
Antoni, FA .
FRONTIERS IN NEUROENDOCRINOLOGY, 2000, 21 (02) :103-132
[7]   Short-term plasticity of cyclic adenosine 3′,5′-monophosphate signaling in anterior pituitary corticotrope cells:: The role of adenylyl cyclase isotypes [J].
Antoni, FA ;
Sosunov, AA ;
Haunso, A ;
Paterson, JM ;
Simpson, J .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) :692-703
[8]  
ANTONI FA, 1995, J BIOL CHEM, V270, P28055
[9]   Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved? [J].
Bankir, L ;
Ahloulay, M ;
Devreotes, PN ;
Parent, CA .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 282 (03) :F376-F392
[10]  
BARBER R, 1981, MOL PHARMACOL, V19, P38